Paclitaxel

For research use only. Not for use in humans.

製品コードS1150 別名:NSC 125973

Paclitaxel化学構造

分子量(MW):853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 17100 あり
JPY 13600 あり
JPY 46800 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(125)

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
ターゲット
Microtubule (human endothelial cells) [1]
0.1 pM
体外試験

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzqOoxKSzVyPUCuNFAxOjh5IN88US=> NHvqRpVUSU6JRWK=
LC-2-ad MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy0Z5p3UUN3ME2wMlAxODNzNzFOwG0> MoPoV2FPT0WU
RL95-2 NGfIZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G0dGlEPTB;MD6wNFA3PjhizszN MVnTRW5ITVJ?
MZ1-PC NW\sW3h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTSTWM2OD1yLkCwNFczQSEQvF2= MoO5V2FPT0WU
TE-8 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v6cGlEPTB;MD6wNFEyPyEQvF2= Mo\1V2FPT0WU
SW954 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT5b5EzUUN3ME2wMlAxOTF7IN88US=> M3zJenNCVkeHUh?=
TE-11 NUm0UGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn1TWM2OD1yLkCwNVI{KM7:TR?= NWHR[nV[W0GQR1XS
PSN1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jTcmlEPTB;MD6wNFE{KM7:TR?= MYHTRW5ITVJ?
MOLT-4 NHPseWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMECxOFkh|ryP NHezfYhUSU6JRWK=
697 NYGycpBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XobmlEPTB;MD6wNFE2KM7:TR?= MkfvV2FPT0WU
ETK-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInt[HlKSzVyPUCuNFAyPTJizszN MWHTRW5ITVJ?
TE-10 NH[xOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGxcFVlUUN3ME2wMlAxOTV2IN88US=> NF[1WpZUSU6JRWK=
HUTU-80 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSwTGpkUUN3ME2wMlAxOTZ6IN88US=> NFLBeYJUSU6JRWK=
NTERA-S-cl-D1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDibFlRUUN3ME2wMlAxOjB7IN88US=> NXW0d4RPW0GQR1XS
MFH-ino MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMECyOlgh|ryP M4P6OHNCVkeHUh?=
IA-LM NWnlU4JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTlTWM2OD1yLkCwNlgh|ryP MmTiV2FPT0WU
MC116 NFvzSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoezTWM2OD1yLkCwNlg6KM7:TR?= M4DRbnNCVkeHUh?=
RKO NWXyRXN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e0NWlEPTB;MD6wNFI6QCEQvF2= M3jKV3NCVkeHUh?=
MRK-nu-1 NVPIVlAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMECyPVkh|ryP MXzTRW5ITVJ?
VA-ES-BJ MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYThXZZOUUN3ME2wMlAxOyEQvF2= NEHqe2NUSU6JRWK=
KALS-1 MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC0NZhKSzVyPUCuNFA{ODhizszN NFvlcXlUSU6JRWK=
BB30-HNC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfZ[HNFUUN3ME2wMlAxOzF2IN88US=> MVrTRW5ITVJ?
ACN NUfqUY9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3vNZZKSzVyPUCuNFA{OTZizszN NIrnbJdUSU6JRWK=
TE-9 NH7XbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHOVW5KSzVyPUCuNFA{OjZizszN M4\seXNCVkeHUh?=
SIG-M5 NYTYTVBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLOTWM2OD1yLkCwN|I4KM7:TR?= MlPsV2FPT0WU
no-10 NYjESJBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjYXJI3UUN3ME2wMlAxOzZ{IN88US=> Ml;HV2FPT0WU
EW-1 M1P0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLQTWM2OD1yLkCwN|cyKM7:TR?= Mo\0V2FPT0WU
SK-LMS-1 NIj6T5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMEC0NFEh|ryP NVvSdWpnW0GQR1XS
GT3TKB NFGyfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTwTWM2OD1yLkCwOFM1KM7:TR?= NWjzZpRyW0GQR1XS
ES4 NH[yUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf0R|BKSzVyPUCuNFA1PDlizszN MVPTRW5ITVJ?
IMR-5 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TKZmlEPTB;MD6wNFQ2KM7:TR?= M{O4WnNCVkeHUh?=
NCI-H1648 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3lTWM2OD1yLkCwOFY6KM7:TR?= NEPXU2lUSU6JRWK=
MV-4-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzFT2VKSzVyPUCuNFA1PzVizszN NGr2UFlUSU6JRWK=
SK-UT-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMEC0PEDPxE1? M1ewSHNCVkeHUh?=
NB13 NXLRTYJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rRU2lEPTB;MD6wNFQ6OSEQvF2= M3;qO3NCVkeHUh?=
DJM-1 NYrCSpM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DteGlEPTB;MD6wNFU{KM7:TR?= NYDCWGlQW0GQR1XS
ES8 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEC1N|gh|ryP MYHTRW5ITVJ?
TE-6 M4PM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXXT2pKSzVyPUCuNFA2PyEQvF2= NWLVWmNuW0GQR1XS
KS-1 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfGTWM2OD1yLkCwOVgzKM7:TR?= MofDV2FPT0WU
TE-1 NHPZTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMEC2NFYh|ryP NVqx[mtbW0GQR1XS
ATN-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTuTWM2OD1yLkCwOlA6KM7:TR?= NWjOUJd5W0GQR1XS
A4-Fuk MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7nTWM2OD1yLkCwOlEyKM7:TR?= MXrTRW5ITVJ?
ALL-PO MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMEC2N{DPxE1? M{\CdXNCVkeHUh?=
BE-13 NHnGbYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP4TWM2OD1yLkCwOlM3KM7:TR?= NXjRUmxxW0GQR1XS
KM12 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLkVmlOUUN3ME2wMlAxPjN5IN88US=> MoHkV2FPT0WU
NOS-1 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEC2OUDPxE1? NFTvdmtUSU6JRWK=
SW962 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLwTWM2OD1yLkCwOlYzKM7:TR?= MkixV2FPT0WU
OCUB-M MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7MdGZ5UUN3ME2wMlAxPjZ{IN88US=> NF70d4FUSU6JRWK=
NCI-H510A M4ra[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DObGlEPTB;MD6wNFY3PSEQvF2= MnL4V2FPT0WU
EW-16 M3PYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XNbGlEPTB;MD6wNFY6PCEQvF2= NFT0cZpUSU6JRWK=
KGN NWHmO2VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPsSJRKSzVyPUCuNFA4OTJizszN MofBV2FPT0WU
LS-411N NXXPSXFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7Wc5M6UUN3ME2wMlAxPzF5IN88US=> MnuxV2FPT0WU
Becker NGXVZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLPTWM2OD1yLkCwO|Ih|ryP MV3TRW5ITVJ?
HC-1 NULXN2pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H1dmlEPTB;MD6wNFczOSEQvF2= NGD6e4xUSU6JRWK=
CESS MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PZPWlEPTB;MD6wNFc{PyEQvF2= NF\lT4VUSU6JRWK=
KURAMOCHI MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\yTWM2OD1yLkCwO|Q5KM7:TR?= M{PhWXNCVkeHUh?=
TGBC24TKB MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMEC3OVIh|ryP M{XrTnNCVkeHUh?=
SW982 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEC3OlYh|ryP MomwV2FPT0WU
HCE-4 NGLBUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[2TWM2OD1yLkCwO|Y4KM7:TR?= MWHTRW5ITVJ?
LOUCY NX;MOpk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzNTWM2OD1yLkCwO|c2KM7:TR?= MVHTRW5ITVJ?
8-MG-BA MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMEC3PVYh|ryP NGrNRolUSU6JRWK=
HT-144 M{TENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPt[pVUUUN3ME2wMlAxQCEQvF2= NYLB[FFyW0GQR1XS
LXF-289 NYLR[JV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMEC4NVgh|ryP MXjTRW5ITVJ?
RS4-11 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMEC4N|Yh|ryP MWfTRW5ITVJ?
DEL NIW0SpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO0TWM2OD1yLkCwPFQ2KM7:TR?= NYrHeHVbW0GQR1XS
OCI-AML2 M1PPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf6TWM2OD1yLkCwPFUzKM7:TR?= NYX0SJRbW0GQR1XS
CCRF-CEM NVLNbZYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHkTWM2OD1yLkCwPFcyKM7:TR?= NI\n[oJUSU6JRWK=
A388 NGfVTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\K[mlEPTB;MD6wNFg4PCEQvF2= MUTTRW5ITVJ?
KNS-42 M2W5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEC4PVEh|ryP MVvTRW5ITVJ?
OVCAR-4 MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMEC5NFQh|ryP MnvKV2FPT0WU
NCI-H1355 NGPS[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\UWVFKSzVyPUCuNFA6OTRizszN M165VXNCVkeHUh?=
BL-70 M1fKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHJVWFqUUN3ME2wMlAxQTNizszN MYfTRW5ITVJ?
BL-41 Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMEC5N|Qh|ryP M3TOfnNCVkeHUh?=
A101D MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHt[GRrUUN3ME2wMlAxQTZizszN M2XiVHNCVkeHUh?=
HL-60 NY\6SZdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDyTWM2OD1yLkCwPVY3KM7:TR?= NHflT|dUSU6JRWK=
COR-L279 M2m1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEC5PVkh|ryP MkCwV2FPT0WU
NCI-SNU-16 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rKXmlEPTB;MD6wNVAxQCEQvF2= MVXTRW5ITVJ?
Calu-6 MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TQ[2lEPTB;MD6wNVAyOiEQvF2= Mm\6V2FPT0WU
SR MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnz[GhKSzVyPUCuNFExOjZizszN NF7Mb|dUSU6JRWK=
QIMR-WIL M{SzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO5TWM2OD1yLkCxNFM{KM7:TR?= NXTDbG4yW0GQR1XS
LB647-SCLC NUPwdlhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr3c|lKSzVyPUCuNFExPTFizszN NY\4UZRkW0GQR1XS
RPMI-8226 NGTHTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jySGlEPTB;MD6wNVExOiEQvF2= M{\ucXNCVkeHUh?=
SK-PN-DW M1Gxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XHXmlEPTB;MD6wNVEyOiEQvF2= M4Kwe3NCVkeHUh?=
SF268 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEGxOVEh|ryP MnqyV2FPT0WU
HD-MY-Z NXfGWnZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XNbGlEPTB;MD6wNVE3OyEQvF2= M4DnS3NCVkeHUh?=
DOHH-2 M4jRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVSzRo1XUUN3ME2wMlAyOjB|IN88US=> MmrsV2FPT0WU
SCC-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMEGyNFQh|ryP NWfiTohrW0GQR1XS
ST486 NH7ONZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zpcGlEPTB;MD6wNVIxPCEQvF2= MWjTRW5ITVJ?
NALM-6 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPUeG1jUUN3ME2wMlAyOjF2IN88US=> M4exUnNCVkeHUh?=
NCI-H1436 M{H4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfzXXJKSzVyPUCuNFEzOzFizszN NGLuNIRUSU6JRWK=
KE-37 M4PtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H0XmlEPTB;MD6wNVI{PCEQvF2= M2LPWXNCVkeHUh?=
RPMI-8402 Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n3dmlEPTB;MD6wNVI2PiEQvF2= MUjTRW5ITVJ?
RXF393 NXjzOlFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv1[25KSzVyPUCuNFEzPTdizszN NVzwOJpxW0GQR1XS
KARPAS-45 NH\IbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMEGyO{DPxE1? MWrTRW5ITVJ?
HOP-62 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXwUWZKSzVyPUCuNFEzPzZizszN NX2yXIZNW0GQR1XS
ES1 NHPHd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO2dG5xUUN3ME2wMlAyOjh6IN88US=> NGTrSmtUSU6JRWK=
L-363 NHTLTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly1TWM2OD1yLkCxN|UyKM7:TR?= NUjoSm1vW0GQR1XS
GI-1 NUjSVXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMEGzO|Mh|ryP M3XaRXNCVkeHUh?=
CTV-1 NXntc5dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrIVIppUUN3ME2wMlAyPDd6IN88US=> NV7aU4hyW0GQR1XS
TE-5 M2\PTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj0TWM2OD1yLkCxOFk3KM7:TR?= MlPLV2FPT0WU
SNU-C2B NUnrXXliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HDcGlEPTB;MD6wNVQ6PiEQvF2= M4LFeHNCVkeHUh?=
K-562 MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj0TWM2OD1yLkCxOVE3KM7:TR?= NIq3S3JUSU6JRWK=
SNB75 MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMEG1OEDPxE1? NYDW[W1mW0GQR1XS
MOLT-13 NITvVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEG2N|ch|ryP NH3SR5dUSU6JRWK=
LS-123 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHkWFFKSzVyPUCuNFE3PjRizszN MoTyV2FPT0WU
NCI-SNU-5 NIezcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMEG3NFEh|ryP M3fmdHNCVkeHUh?=
Daudi NGrtdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\OTWM2OD1yLkCxO|A5KM7:TR?= M2PtbnNCVkeHUh?=
A253 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLGO3VwUUN3ME2wMlAyPzN6IN88US=> M3G5PHNCVkeHUh?=
TGBC1TKB MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH4d3NKSzVyPUCuNFE4PTJizszN MoDyV2FPT0WU
SJSA-1 M3ezbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rWU2lEPTB;MD6wNVc3PyEQvF2= NVXjfHVHW0GQR1XS
NCCIT MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r3UGlEPTB;MD6wNVc3QSEQvF2= NUH2VIdOW0GQR1XS
NCI-H69 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PnNGlEPTB;MD6wNVc4QCEQvF2= MnzkV2FPT0WU
SH-4 NGfweI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHDTWM2OD1yLkCxPFk2KM7:TR?= M2rJW3NCVkeHUh?=
HCC1187 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHS[Ys4UUN3ME2wMlAyQTJ2IN88US=> M1jTPXNCVkeHUh?=
HCC1599 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrCU5p6UUN3ME2wMlAzODJizszN M2fsTHNCVkeHUh?=
ONS-76 NH\CNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMEKwN|Yh|ryP M4L2UnNCVkeHUh?=
KU812 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7vRXE4UUN3ME2wMlAzODN7IN88US=> MnTUV2FPT0WU
ML-2 NGLYNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmftTWM2OD1yLkCyNFQ4KM7:TR?= M2XYfHNCVkeHUh?=
HCE-T NVfm[WRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO2XZFFUUN3ME2wMlAzODl{IN88US=> MmO1V2FPT0WU
NCI-H446 NFLnSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHZTWM2OD1yLkCyNVEzKM7:TR?= MUfTRW5ITVJ?
RPMI-6666 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnaeo1uUUN3ME2wMlAzOTR7IN88US=> MXfTRW5ITVJ?
MOLT-16 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrRTHdKSzVyPUCuNFIyPTNizszN MnHuV2FPT0WU
JiyoyeP-2003 MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW3UIlKSzVyPUCuNFIyPzZizszN MYXTRW5ITVJ?
MHH-PREB-1 NF3uPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMEKxPVEh|ryP NFnWeVJUSU6JRWK=
MC-CAR NXXKNFFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\xTWM2OD1yLkCyN|I3KM7:TR?= MmfaV2FPT0WU
BC-3 NXTVO5ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnTdYVHUUN3ME2wMlAzOzR2IN88US=> MUDTRW5ITVJ?
KINGS-1 MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvLXXVKSzVyPUCuNFI{PTVizszN NV6zRmNzW0GQR1XS
PF-382 M4\xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMEKzO|gh|ryP NFjyfmJUSU6JRWK=
J-RT3-T3-5 NX3He|dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXGTFhKSzVyPUCuNFI{QDNizszN M1LWNHNCVkeHUh?=
SF539 MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrYW5U{UUN3ME2wMlAzPDBzIN88US=> MkLUV2FPT0WU
LB831-BLC NE\IOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TTb2lEPTB;MD6wNlQ5PSEQvF2= M17WSnNCVkeHUh?=
DMS-114 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\xUmlEPTB;MD6wNlUxOiEQvF2= MV7TRW5ITVJ?
LB1047-RCC NYjhV3FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT3TWM2OD1yLkCyOVEh|ryP NYG3UHRyW0GQR1XS
LB771-HNC MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDuTWM2OD1yLkCyOVM1KM7:TR?= NFW2[WpUSU6JRWK=
BB65-RCC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHh[m9FUUN3ME2wMlAzPTN2IN88US=> NH;KRXhUSU6JRWK=
BV-173 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zv[2lEPTB;MD6wNlU2PCEQvF2= MV7TRW5ITVJ?
ARH-77 NFXT[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTrTWM2OD1yLkCyOlAyKM7:TR?= MV;TRW5ITVJ?
IST-MEL1 MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HUR2lEPTB;MD6wNlYzOyEQvF2= M{\XcHNCVkeHUh?=
NB1 NX;QN5JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf2NYFzUUN3ME2wMlAzPjh5IN88US=> NF31NYxUSU6JRWK=
EoL-1-cell MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S5d2lEPTB;MD6wNlY5QCEQvF2= NH\lRm9USU6JRWK=
KY821 NV;ScXZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLNVVlKSzVyPUCuNFI3QTdizszN NWLL[mN5W0GQR1XS
CMK NUS1bY1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonpTWM2OD1yLkCyO|M1KM7:TR?= NU\Nd4t[W0GQR1XS
NCI-H2126 NVflSW1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEK3Olgh|ryP M3rDUnNCVkeHUh?=
NCI-H526 NX2x[VVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonaTWM2OD1yLkCyPFkyKM7:TR?= M2rjOXNCVkeHUh?=
COLO-684 NH\GcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkKwTWM2OD1yLkCyPVA5KM7:TR?= MmDFV2FPT0WU
NCI-H747 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LIbmlEPTB;MD6wNlk{OyEQvF2= M2PxTHNCVkeHUh?=
JAR MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEK5OFYh|ryP NHvRTolUSU6JRWK=
MEG-01 NUXNfYl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPUblZLUUN3ME2wMlAzQTd6IN88US=> NF7TW2pUSU6JRWK=
MONO-MAC-6 Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3YTWM2OD1yLkCzNFI{KM7:TR?= MlPZV2FPT0WU
IST-SL1 Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljRTWM2OD1yLkCzNFQzKM7:TR?= M4PSXXNCVkeHUh?=
CPC-N MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjMXGl2UUN3ME2wMlA{ODd7IN88US=> MoXEV2FPT0WU
NCI-H1963 M16ze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M336Z2lEPTB;MD6wN|E{OSEQvF2= NVrmU2xWW0GQR1XS
K052 M3vubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;5TmlEPTB;MD6wN|I1PyEQvF2= MkXBV2FPT0WU
KM-H2 NIrhcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHPTXJVUUN3ME2wMlA{OzB5IN88US=> MnLhV2FPT0WU
TE-12 MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnmcmxKSzVyPUCuNFM{ODlizszN M1rKc3NCVkeHUh?=
TK10 NX7Od2lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDqTWM2OD1yLkCzN|U3KM7:TR?= Ml3DV2FPT0WU
NMC-G1 NVXHPIJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMEO0OVIh|ryP NVHUPHFvW0GQR1XS
no-11 NVviPZNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGxUJU5UUN3ME2wMlA{PDd6IN88US=> M3zYU3NCVkeHUh?=
NCI-H524 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\NTWM2OD1yLkCzOVI6KM7:TR?= MWnTRW5ITVJ?
MHH-CALL-2 NY\CR|l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMEO1OlIh|ryP NGHVbJdUSU6JRWK=
GB-1 NXHoflNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqzTWM2OD1yLkCzOkDPxE1? M1L6VHNCVkeHUh?=
OPM-2 NVG4cWlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEO2O|Mh|ryP NUjVZ3lUW0GQR1XS
RH-1 MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\IN2VLUUN3ME2wMlA{QDF7IN88US=> NFnUOoFUSU6JRWK=
NCI-H64 NEPkO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;4VmlCUUN3ME2wMlA{QDV5IN88US=> NWPaNmFPW0GQR1XS
EVSA-T NETwbopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEO5NlMh|ryP MmP2V2FPT0WU
KARPAS-299 MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPHcVlKSzVyPUCuNFM6QCEQvF2= Moe0V2FPT0WU
MZ7-mel NFLEfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rMOGlEPTB;MD6wOFA1KM7:TR?= MnrlV2FPT0WU
LB373-MEL-D M1y2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz4S3hIUUN3ME2wMlA1OTB3IN88US=> MXTTRW5ITVJ?
HEL NYD0ZnRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMESxOEDPxE1? MlfEV2FPT0WU
SW872 NVnSZ2RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMESyNUDPxE1? M37ZVXNCVkeHUh?=
DU-4475 Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq3TWM2OD1yLkC0NlQ1KM7:TR?= MXrTRW5ITVJ?
IST-SL2 M3rpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7HTnB1UUN3ME2wMlA1Ojd3IN88US=> NWTMZ2Y5W0GQR1XS
NCI-H82 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDXS|lIUUN3ME2wMlA1OzB5IN88US=> NWLURVRDW0GQR1XS
LC4-1 MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPKUXN3UUN3ME2wMlA1OzVzIN88US=> Mn;vV2FPT0WU
HDLM-2 NH3VN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3pUHFKSzVyPUCuNFQ{QTJizszN M1OycnNCVkeHUh?=
MMAC-SF MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DIb2lEPTB;MD6wOFU{PCEQvF2= NI\ZZY9USU6JRWK=
L-540 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwMES2N|kh|ryP NFTibHpUSU6JRWK=
MZ2-MEL M1T0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXiOHpQUUN3ME2wMlA1PzR{IN88US=> M33aW3NCVkeHUh?=
LU-134-A MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojXTWM2OD1yLkC0O|c{KM7:TR?= NHrwRVJUSU6JRWK=
UACC-257 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMES4OFkh|ryP MXHTRW5ITVJ?
NCI-H1581 MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33vUmlEPTB;MD6wOFk2OyEQvF2= NXv0ZnBzW0GQR1XS
NB17 NYK4d5NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfjTWM2OD1yLkC0PVc6KM7:TR?= MYTTRW5ITVJ?
SBC-1 Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfpTWM2OD1yLkC1NFQzKM7:TR?= NVHvS3FQW0GQR1XS
TALL-1 NWfMTI53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rB[2lEPTB;MD6wOVA1PSEQvF2= M1m0dnNCVkeHUh?=
NCI-H1304 NITXVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLHOoFbUUN3ME2wMlA2OjB6IN88US=> Ml;6V2FPT0WU
NEC8 M3\MbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Hl[mlEPTB;MD6wOVI5PiEQvF2= NGHPS4FUSU6JRWK=
CAL-148 M3GyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETleFlKSzVyPUCuNFU1OzlizszN M2XafHNCVkeHUh?=
CGTH-W-1 M1XEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7FTWM2OD1yLkC1OFQ6KM7:TR?= MXXTRW5ITVJ?
NCI-H889 M4Hpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP1UIFKSzVyPUCuNFU2QTJizszN NETtTYZUSU6JRWK=
GR-ST MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH6e3N7UUN3ME2wMlA2PjJzIN88US=> M1PGeHNCVkeHUh?=
KARPAS-422 NHzS[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvrTWM2OD1yLkC1OlUh|ryP MVPTRW5ITVJ?
RPMI-8866 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\KN2lEPTB;MD6wOVcyOiEQvF2= NU\LTpdEW0GQR1XS
SCLC-21H M163WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfETWM2OD1yLkC1PFg1KM7:TR?= NH\ZSlVUSU6JRWK=
COR-L88 NGjIbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX76O|FlUUN3ME2wMlA2QTJ5IN88US=> NXfYbIF7W0GQR1XS
LU-139 NYHlNFF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMEW5PFYh|ryP MU\TRW5ITVJ?
SF126 M4rjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXpVIRKSzVyPUCuNFYyOzNizszN MV3TRW5ITVJ?
NCI-H1882 NUDEXXVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTwXlUzUUN3ME2wMlA3PDJ2IN88US=> M3jRcnNCVkeHUh?=
EW-24 NFjaPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fiNWlEPTB;MD6wOlQ5OyEQvF2= NWj1dlBSW0GQR1XS
CP67-MEL M1nzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rkb2lEPTB;MD6wOlgyKM7:TR?= M3SzUHNCVkeHUh?=
DG-75 NWPGNZEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi5TWM2OD1yLkC2PFk6KM7:TR?= MV;TRW5ITVJ?
LOXIMVI MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP2VG9KSzVyPUCuNFcxOjhizszN MXfTRW5ITVJ?
HH NVT0c5A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq3TWM2OD1yLkC3NVU4KM7:TR?= NIjrNFRUSU6JRWK=
K5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n6R2lEPTB;MD6wO|IzPiEQvF2= MXzTRW5ITVJ?
EC-GI-10 Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfiSWZIUUN3ME2wMlA4OjV5IN88US=> NXm1SnFqW0GQR1XS
SK-N-DZ NXHWdotZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LlSGlEPTB;MD6wO|MxPyEQvF2= MXzTRW5ITVJ?
A3-KAW NVLSTXB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkftTWM2OD1yLkC3N|UyKM7:TR?= MVjTRW5ITVJ?
MLMA NULrNWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTxZohKSzVyPUCuNFc1PjVizszN Ml\HV2FPT0WU
LB996-RCC M1\WO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMEe3NFch|ryP NWDOPXhzW0GQR1XS
OS-RC-2 NGDCVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfxc282UUN3ME2wMlA4PzR6IN88US=> MUPTRW5ITVJ?
CTB-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILTd3pKSzVyPUCuNFc5OSEQvF2= M4PiO3NCVkeHUh?=
IST-MES1 MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PC[GlEPTB;MD6wO|kyOiEQvF2= NH34c|hUSU6JRWK=
LS-1034 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;ZTWM2OD1yLkC4NFM2KM7:TR?= NYHaTpNQW0GQR1XS
HT Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMEiwPFYh|ryP MknJV2FPT0WU
NCI-H2141 NVqzNpdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PsXGlEPTB;MD6wPFEh|ryP M3u1RXNCVkeHUh?=
LB2518-MEL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPhR|JKSzVyPUCuNFgyPDFizszN MnfwV2FPT0WU
GI-ME-N MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTLPVNNUUN3ME2wMlA5PDV{IN88US=> M1XGb3NCVkeHUh?=
TGW MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\kUlNKSzVyPUCuNFg3ODdizszN NFjp[GlUSU6JRWK=
SK-NEP-1 NV7iPXlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknoTWM2OD1yLkC4OlQyKM7:TR?= NE\zWJBUSU6JRWK=
NOMO-1 NUT2ZllDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPLbnhwUUN3ME2wMlA6Ojd3IN88US=> MYDTRW5ITVJ?
ES6 NVW4eWlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMEm1PFkh|ryP NV\U[3NQW0GQR1XS
NCI-H209 M3:1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7z[FNiUUN3ME2wMlA6Pzh4IN88US=> NHLUO|RUSU6JRWK=
GAK M{fm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fGPGlEPTB;MD6xNFE3KM7:TR?= M{LyOXNCVkeHUh?=
BC-1 MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nseGlEPTB;MD6xNFM3OSEQvF2= M2n1T3NCVkeHUh?=
KLE NH2zbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnTboRKSzVyPUCuNVA1PDNizszN NEna[GJUSU6JRWK=
EW-3 M4LSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnmTWM2OD1yLkGwPVgh|ryP M2\jXXNCVkeHUh?=
NKM-1 M4PQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrRVlRKSzVyPUCuNVEyKM7:TR?= NGrpPWNUSU6JRWK=
D-336MG NVnXWZBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnwTWM2OD1yLkGxNlQ1KM7:TR?= MVHTRW5ITVJ?
NB69 Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL5[Zp5UUN3ME2wMlEyOzBzIN88US=> NIP3OY5USU6JRWK=
D-263MG NIP3TndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\3dJpKSzVyPUCuNVE4OTJizszN NYPUWoNDW0GQR1XS
KP-N-YS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMUKyPVEh|ryP Mkj2V2FPT0WU
NCI-H1155 NWXh[FVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHYcFdKSzVyPUCuNVI2PThizszN NYLqdVhsW0GQR1XS
BOKU NIPndHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV23R|VvUUN3ME2wMlEzPTd7IN88US=> NXKxZoQ5W0GQR1XS
LAMA-84 NV:zV3JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXLVWlKSzVyPUCuNVI6QSEQvF2= M1TjZ3NCVkeHUh?=
Raji M{\EVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPSTWM2OD1yLkGzNVE4KM7:TR?= MljvV2FPT0WU
LU-65 M4q4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTzNnk{UUN3ME2wMlE{OzB5IN88US=> Mn7JV2FPT0WU
NCI-H187 M361c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjYR28yUUN3ME2wMlE{QTJ2IN88US=> NYG0VIFFW0GQR1XS
GCIY MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXq1[WRxUUN3ME2wMlE1QTBzIN88US=> M1vMW3NCVkeHUh?=
NCI-H2107 NUjONYNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO3d|NKSzVyPUCuNVUxQCEQvF2= M4nlUXNCVkeHUh?=
NCI-H1522 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjlUpJKSzVyPUCuNVUzPjZizszN MVTTRW5ITVJ?
NB6 MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL2WpZKSzVyPUCuNVU3OjNizszN M{PJbXNCVkeHUh?=
EM-2 NIOzb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMUW3NFYh|ryP M1vsOXNCVkeHUh?=
HCC2218 M4PJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMUW5PEDPxE1? MVXTRW5ITVJ?
NCI-H748 NI\xb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XDO2lEPTB;MD6xOlM4PiEQvF2= Mkj5V2FPT0WU
MS-1 M{LsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\Vb2lEPTB;MD6xOlU{PyEQvF2= MV3TRW5ITVJ?
NB5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfUZ3lKSzVyPUCuNVY2QTdizszN NF7GSVFUSU6JRWK=
OMC-1 NVH4WVhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPyTWM2OD1yLkG2Olg5KM7:TR?= NHT6OpVUSU6JRWK=
NCI-H345 NVrv[IRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPmUnZKSzVyPUCuNVY6OjhizszN NEjLcnZUSU6JRWK=
L-428 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33PUWlEPTB;MD6xOlk1PSEQvF2= NUP0bXd4W0GQR1XS
SCH MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLWVVh7UUN3ME2wMlE5Pjh3IN88US=> MVTTRW5ITVJ?
NCI-H1417 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMUmyNlch|ryP M4LJe3NCVkeHUh?=
COLO-320-HSR NEjlc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMUm1N|Ih|ryP M4PIV3NCVkeHUh?=
BT-474 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrUWGtFUUN3ME2wMlIxQDl{IN88US=> NGjsOGZUSU6JRWK=
GDM-1 NVXxeW1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMkG5O|Eh|ryP NFz0dIxUSU6JRWK=
NCI-H2196 NFvFR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnXd4VuUUN3ME2wMlIzOjN3IN88US=> NEX3e5dUSU6JRWK=
KP-N-RT-BM-1 NVXYZVR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq1WWVKSzVyPUCuNlI{PDlizszN NITZSIVUSU6JRWK=
KNS-81-FD MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\GWmlEPTB;MD6yNlk2QCEQvF2= M4nrbXNCVkeHUh?=
COLO-668 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMkO2O|Uh|ryP M3u5V3NCVkeHUh?=
C2BBe1 MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInPfWxKSzVyPUCuNlY4PDdizszN MXjTRW5ITVJ?
Ramos-2G6-4C10 M1vCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMk[5OVQh|ryP NUnJVVN6W0GQR1XS
CAS-1 M13Xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMkewPVYh|ryP M2noNHNCVkeHUh?=
GOTO MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LocWlEPTB;MD6yO|g6PCEQvF2= NUXxPIdEW0GQR1XS
LP-1 NV\zbGdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMkiwOVch|ryP MWnTRW5ITVJ?
NCI-SNU-1 NYm2b4ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC3TWM2OD1yLkK5OFIzKM7:TR?= MofOV2FPT0WU
EB-3 M1jPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ziWWlEPTB;MD6yPVk4QSEQvF2= NIX4bZRUSU6JRWK=
MHH-NB-11 MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3SV5RCUUN3ME2wMlMxPDB{IN88US=> M{D4[HNCVkeHUh?=
SK-N-FI NGDC[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXpfJVKSzVyPUCuN|E3QTJizszN MXTTRW5ITVJ?
HCC2157 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HMXmlEPTB;MD6zN|kyOyEQvF2= NEnheYZUSU6JRWK=
SIMA NV3BOo5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHIW4xKSzVyPUCuN|Q2QDFizszN MlHEV2FPT0WU
MDA-MB-134-VI NH7sZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\Ud4VKSzVyPUCuN|Y6OjhizszN NV;JXmtqW0GQR1XS
NCI-H1694 MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q2VGlEPTB;MD6zO{DPxE1? M4DyRXNCVkeHUh?=
EHEB M1fFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrBTWM2OD1yLkO5NFg2KM7:TR?= MVjTRW5ITVJ?
U-266 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWySZdKSzVyPUCuN|k5PDZizszN M1O3N3NCVkeHUh?=
LC-1F M3rnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXzbWdKSzVyPUCuOFM4PjVizszN Mkn5V2FPT0WU
SHP-77 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHvTWM2OD1yLkS3PFU2KM7:TR?= NVnPNHRwW0GQR1XS
LS-513 MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7ZTWM2OD1yLkS5N|A4KM7:TR?= M1XES3NCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-ERK / ERK; 

PubMed: 20068074     


Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells.

MARCKS (pSer159/163); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

Src (pTyr416); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; 

PubMed: 29849942     


OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot.

Id1; 

PubMed: 25344919     


(A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner.

MARCKS; 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

20068074 26015406 29849942 25344919
Growth inhibition assay
Cell viability; 

PubMed: 28823711     


Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.

28823711
Immunofluorescence
α-tubulin; 

PubMed: 22904633     


Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel.

Rab11a/BV9; 

PubMed: 29290815     


Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).

22904633 29290815
体内試験

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

- 合併
  • 細胞株: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • 濃度: 0.1-100 pM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (参考用のみ)
動物試験:

[4]

- 合併
  • 動物モデル: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • 製剤: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • 投薬量: 20 mg/kg
  • 投与方法: Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
6mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管
in solvent
別名 NSC 125973
Smiles CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)C4=CC=CC=C4)C5(O)CC(OC(=O)C(O)C(NC(=O)C6=CC=CC=C6)C7=CC=CC=C7)C(=C1C5(C)C)C

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04000906 Not yet recruiting Drug: NAB paclitaxel|Drug: Cisplatin Peritoneal Carcinomatosis University Hospital Geneva September 2019 Phase 1
NCT04046887 Not yet recruiting Drug: Lonsurf|Drug: Gemcitabine|Drug: Nab-Paclitaxel Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma Patrick Joseph Loehrer Sr.|Indiana University|Taiho Oncology Inc. August 2019 Phase 1
NCT03779464 Recruiting Drug: S1 or Gemcitabine Pancreatic Cancer|Nab-paclitaxel|Gemcitabine|S1 Wuhan Union Hospital China August 1 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 質問2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associatedシグナル伝達経路

相関Microtubule Associated製品

Tags: Paclitaxelを買う | Paclitaxel ic50 | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel化学構造 | Paclitaxel分子量 | Paclitaxel代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID